Search clinical trials for: YY-351/Placebo

Total 54511 results

Yuyu Pharma, Inc.

Completed

A Dose-Finding, Efficacy and Safety Study of YY-351 in Patients With Type 2 Diabetes

Diabetes

Korea, Republic of
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Relapsed or Refractory Peripheral T-Cell Lymphoma

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

PTCL
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

Indolent B-cell Lymphoma
Ruijin Hospital
Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting

Real World Study of Linperlisib for Lymphoma Treatment (MA-LYM-RWS-001)

Focus on the Lymphoma Including B/T-cell Lymphoma

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer

Effectiveness，Safety，Thymic Cancer
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma

Lymphoma, Follicular

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Recruiting

A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

Peripheral T/NK Cell Lymphoma (R/R PTCL)

United States
University of Copenhagen
EC-FP6 (contract number: LHM-CT-2003-503041); Aditech Pharma AB

Completed

The Role of Peptide YY (PYY)Infusions in Inhibiting Food Intake.

Obesity
University of Copenhagen
Aditech Pharma AB

Completed

The Role of Peptide YY (PYY)in Inhibiting Food Intake.

Obesity
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2)

Dyslipidemias

Korea, Republic of
Cryonove Pharma
CEISO; Dermatech; LTD HEALTH

Completed

Tolerance and Performance (Mode of Administration) of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots

Lentigo Solar | Senile Lentigo

Georgia
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma

Follicular Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Gila Therapeutics, Inc.

Completed

A Dose Escalating Study to Assess the Safety and Tolerability of GT-001

Feeding and Eating Disorders

United States
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Ocular Hypertension | Primary Open-angle Glaucoma

Korea, Republic of
Yuyu Pharma, Inc.

Completed

Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder) (ADHD)

Mental Disorders

Korea, Republic of
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

B-cell Chronic Lymphocytic Leukemia | B-cell Lymphoma Recurrent

China
Hoya Surgical Optics, Inc.

Completed

Visual Quality Following Aspheric Intraocular Lens (IOL) Implantation - a Comparative Clinical Study (751)

Cataract | Aphakia

Australia
Yuyu Pharma, Inc.

Completed

Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD (yuyu)

Mental Disorders

Korea, Republic of
Jazz Pharmaceuticals
Iqvia Pty Ltd

Completed

CPX-351 Real-World Effectiveness and Safety Study

Acute Myeloid Leukemia

United Kingdom
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteers

United States
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteer

United States
Chonbuk National University Hospital

Completed

Efficacy and Safety of Chungkookjang on Improvement of Metabolic Syndrome

Metabolic Syndrome

Korea, Republic of
French Innovative Leukemia Organisation
Acute Leukemia French Association; French Intergroup of Myeloproliferative...

Recruiting

Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm (CPX-351 TA-SMP)

Acute Myeloid Leukemia | Myeloproliferative Syndrome

France
Case Comprehensive Cancer Center

Active, not recruiting

CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS

Myelodysplastic Syndromes | Refractory Acute Myeloid Leukemia | Relapsed Acute Myelomonocytic Leukemia

United States
Groupe Francophone des Myelodysplasies

Completed

CPX-351 in Higher Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

France
Global Alliance for TB Drug Development

Terminated

A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

Tuberculosis
BioMarin Pharmaceutical

Recruiting

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer
Solvay Pharmaceuticals

Terminated

Study Evaluating the Safety and Tolerability of Single Ascending Dose (SAD) SLV-351 in Healthy Subjects

Healthy
AJU Pharm Co., Ltd.

Completed

Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients

Type2 Diabetes

Korea, Republic of
Jazz Pharmaceuticals

Completed

A Post-Marketing Observational Study of VYXEOS™

Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
Azitra Inc.

Not yet recruiting

Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

Netherton Syndrome

United States
Chong Kun Dang Pharmaceutical

Recruiting

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia

Primary Hypercholesterolemia

Korea, Republic of
Merck Sharp & Dohme LLC

Withdrawn

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Asthma
ENA Respiratory Pty Ltd

Completed

INNA-051 Influenza Challenge Study

Influenza Prophylaxis

United Kingdom
Akros Pharma Inc.

Terminated

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR-PS)

Skin Diseases | Plaque Psoriasis

United States, Canada
Akros Pharma Inc.

Completed

Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis (MOVE-RA)

Rheumatoid Arthritis

Ukraine, United States, Argentina, Bulgaria, Romania, Peru, Russian Federation, Mexico, Colombia, Poland
Amgen

Completed

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

Chronic Migraine or Episodic Migraine

United States, Germany, Austria, Czechia, Canada, Denmark, Finland, Sweden
Dart NeuroScience, LLC

Terminated

HT-3951 vs. Placebo in Stroke Rehabilitation (RESTORE)

Ischemic Stroke

United States
Akros Pharma Inc.

Completed

Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects

Skin Diseases | Psoriasis | Plaque Psoriasis

Canada
Akros Pharma Inc.

Completed

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

Anemia of Chronic Kidney Disease

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer Disease

United States
Amgen

Completed

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura
Amgen

Completed

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura
Hoffmann-La Roche

Completed

A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, Netherlands, Italy, Germany, Switzerland, Czechia, Spain
ContraFect

Completed

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)

United States
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

Tuberculosis

United States
Akros Pharma Inc.

Withdrawn

Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension (RELIEF-PAH)

Pulmonary Arterial Hypertension

Search clinical trials for: YY-351/Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations